Literature DB >> 2689039

Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

B R Meyers1, P Wilkinson.   

Abstract

A review of the clinical pharmacokinetics of antibiotics in the healthy elderly reveals that for most compounds a decrease occurs in renal clearance (associated with age-related decreases in renal function), as well as a prolonged half-life and increased area under the plasma concentration-time curve. These changes are amplified in the sick infected elderly. It is important that the treating physician be aware of the potential side-effects of antimicrobial agents, and whenever possible choose those which are associated with the least adverse effects. Individual patient variability, including underlying diseases and other prescribed medications, must be taken into account when dosage is selected. beta-Lactam compounds have a remarkable safety record: specifically in the elderly, their therapeutic/toxic ratio is much higher than that observed with aminoglycosides. Regimens for this class of drugs in the elderly should maintain antibiotic concentrations above the minimum inhibitory concentrations for maximum efficacy. In the treatment of elderly patients, it is suggested that dosage and interval be based on estimated or measured creatinine clearance. Usually, for drugs that are excreted primarily by the kidney (i.e. amino-glycosides, beta-lactams and quinolones), dosage intervals must be increased when there is an associated fall in creatinine clearance. The pharmacokinetic parameters suggest that as an alternative to increasing dosage interval the usual dose may be decreased, but further studies are necessary for confirmation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2689039     DOI: 10.2165/00003088-198917060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  63 in total

Review 1.  Drug use in the elderly: a review of problems and special considerations.

Authors:  R E Vestal
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

2.  Pharmacokinetics of cefotaxime in elderly patients.

Authors:  H Sugihara; K Yoneyama; H Sorimachi; T Kamo; S Imamura; N Akashi; M Yamada; T Shimizu
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Institutional salmonellosis.

Authors:  W B Baine; E J Gangarosa; J V Bennett; W H Barker
Journal:  J Infect Dis       Date:  1973-09       Impact factor: 5.226

4.  Prevalence survey of infections and their predisposing factors at a hospital-based nursing home care unit.

Authors:  T R Franson; E H Duthie; J E Cooper; G Van Oudenhoven; R G Hoffmann
Journal:  J Am Geriatr Soc       Date:  1986-02       Impact factor: 5.562

5.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

6.  Pharmacokinetics of aztreonam in elderly male volunteers.

Authors:  W A Creasey; T B Platt; M Frantz; A A Sugerman
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

7.  [Clinical evaluation of cefoperazone in lower respiratory tract infections].

Authors:  T Ishibashi; M Takamoto; A Shinoda; K Matsuba; M Yoshida; Y Ichikawa; M Ando; Y Matsuzaki; Y Kitahara; N Hara
Journal:  Jpn J Antibiot       Date:  1986-10

8.  Nosocomial infections among patients in a long-term care facility: spectrum, prevalence, and risk factors.

Authors:  U Setia; I Serventi; P Lorenz
Journal:  Am J Infect Control       Date:  1985-04       Impact factor: 2.918

9.  Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections.

Authors:  K G Naber; F Kees; H Grobecker
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

View more
  9 in total

1.  Effects of age and gender on pharmacokinetics of cefepime.

Authors:  R H Barbhaiya; C A Knupp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.

Authors:  Gopal Muralidharan; Richard J Fruncillo; Marlynne Micalizzi; Donald G Raible; Steven M Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 3.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 4.  Quinolones in the aged.

Authors:  L E Nicolle
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Antimicrobial Use in Patients with Dementia: Current Concerns and Future Recommendations.

Authors:  Carole Parsons; Jenny T van der Steen
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 5.749

6.  Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects.

Authors:  O Kozawa; T Uematsu; H Matsuno; M Niwa; Y Takiguchi; S Matsumoto; M Minamoto; Y Niida; M Yokokawa; S Nagashima; M Kanamaru
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Authors:  J Schrenzel; F Cerruti; M Herrmann; T Leemann; E Weidekamm; R Portmann; B Hirschel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers.

Authors:  B R Meyers; P Wilkinson; M H Mendelson; S Walsh; C Bournazos; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  Aging exacerbates mortality of Acinetobacter baumannii pneumonia and reduces the efficacies of antibiotics and vaccine.

Authors:  Hao Gu; Dong Liu; Xi Zeng; Liu-Sheng Peng; Yue Yuan; Zhi-Fu Chen; Quan-Ming Zou; Yun Shi
Journal:  Aging (Albany NY)       Date:  2018-07-18       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.